<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ910405-0029</DOCNO><DOCID>910405-0029.</DOCID><HL>   Collaborative Research   Plans to Sell a Unit   To Becton Dickinson</HL><DATE>04/05/91</DATE><SO>WALL STREET JOURNAL (J), PAGE B6D</SO><CO>   BDX CRIC</CO><MS>CONSUMER NON-CYCLICAL (NCY)TECHNOLOGY (TEC)</MS><IN>MEDICAL SUPPLIES, EYEGLASS MANUFACTURERS (MDS)MEDICAL AND BIOTECHNOLOGY, GENETIC RESEARCH, PROSTHETICS (MTC)TENDER OFFERS, MERGERS, ACQUISITIONS (TNM)</IN><RE>MASSACHUSETTS (MA)NEW JERSEY (NJ)</RE><LP>   BEDFORD, Mass. -- Collaborative Research Inc. said itsigned a letter of intent to sell its biomedical productsunit to Becton Dickinson andamp; Co. for $9 million.   The price, which is subject to certain post-closingadjustments, may include an additional $1.6 million over thenext five years, depending on sales of the unit,Collaborative said.</LP><TEXT>   The biotechnology concern said it will use proceeds todevelop its genetic testing business. The transaction &quot;givesus a new lease on life,&quot; said Orrie M. Friedman, chairman.&quot;We don't have the financial resources to explore newopportunities in biomedical products. And we've sufferedgreat frustration not having enough resources to develop&quot;genetic testing for predisposition to various diseases,including cancer.   Completion of the transaction is subject to a finalagreement, approval of the boards of each company andapproval by two-thirds of Collaborative's shareholders, thecompany said. Collaborative said it hopes to sign adefinitive agreement within 30 days and to hold a specialshareholders meeting to vote on the transaction in latespring or early summer.</TEXT></DOC>